| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| A684 | Roche patent anti-ANG-2 Featured |
|
|
| A685 | Evinacumab Featured | Evinacumab (REGN1500) is a human anti-ANGPTL3 (angiopoietin-like protein 3) monoclonal antibody (IgG4 class antibody). Evinacumab reduces plasma lipids in dyslipidemic mice by blocking ANGPTL3. Evinacumab can be used in studies of homozygous familial hypercholesterolaemia (HoFH), refractory hypercholesterolaemia (both familial and non-familial) and severe hypertriglyceridaemia. |
|
| A686 | Nanyang Tech.U. patent anti-ANGPTL4 Featured |
|
|
| A688 | Novartis patent anti-TMEM16A Featured |
|
|
| A687 | Regeneron patent anti-ANGPTL8 Featured |
|
|
| A689 | Timolumab Featured | Timolumab (BTT1023 ), a recombinant fully human monoclonal antibody that specifically binds VAP-1. Timolumab (BTT1023 ) could be used in the study of chronic inflammatory diseases. |
|
| A690 | Regeneron patent anti-ASIC1 Featured |
|
|
| A691 | Tilvestamab Featured | Tilvestamab (BGB149) is a humanized anti-AXL antibody that blocks AXL-mediated cell signaling. Tilvestamab significantly inhibits Gas6-induced AXL activation in 786-0-Luc RCC cells and inhibits downstream AKT phosphorylation. Tilvestamab can be used in cancer research, particularly in AXL overexpressing renal cell carcinomas. |
|
| A692 | Enapotamab Featured | Enapotamab is an anti-AXL/UFO reference antibody. Enapotamab can be used to synthesis Bcl-xl inhibitor antibody-drug conjugates. |
|
| A693 | Anti-AXL/UFO Antibody (ORY012) Featured |
|
|
| A694 | Pacmilimab Featured | Pacmilimab (CX-072) is a potent PD-L1 inhibitor. Pacmilimab shows antitumor activity. |
|
| A695 | MDX-1105 Featured |
|
|
| A696 | Manelimab Featured | Manelimab is a monoclonal antibody that inhibits programmed death-ligand 1 (PD-L1). |
|
| A697 | Lodapolimab Featured | Lodapolimab (LY3300054) is an IgGλ anti-PD-1 monoclonal antibody. |
|
| A698 | Adebrelimab Featured | Adebrelimab (SHR-1316) is a humanized IgG4 monoclonal PD-L1 (PD-1/PD-L1) antibody. Adebrelimab has promising antitumor activity in solid tumors including extensive-stage small-cell lung cancer (SCLC). |
|
| A699 | Sudubrilimab Featured | Sudubrilimab (HS636) is an Ig G1-kappa monoclonal antibody against PDL1. Sudubrilimab is fused at the C terminus of the heavy chain to a TGF-β1 receptor Ⅱ ectodomain (TGFBR2-ECD), and which can sequester the PD-1/PD-L1 pathway and TGF-β bioactivity in the immunosuppressive tumor microenvironment. |
|
| A700 | Opucolimab Featured | Opucolimab is an anti-PD-L1 recombinant human monoclonal antibody. Opucolimab can be used to synthesis antibody agent conjugates. Opucolimab can be used for the research of advanced solid tumors. |
|
| A701 | Garivulimab Featured | Garivulimab (BGB-A333) is a humanized IgG1-variant monoclonal antibody that specifically targets and binds to PD-L1. Garivulimab selectively blocks the interaction of PD-L1 and PD-1. Garivulimab has antitumor activity. |
|
| A702 | Sugemalimab Featured | Sugemalimab is a fully human, full length, anti-programmed death ligand 1 (PD-L1) immunoglobulin G4 (IgG4) monoclonal antibody (mAb). Sugemalimab shows anticancer activities and can be used for non-small cell lung cancer research. |
|
| A703 | Cosibelimab Featured | Cosibelimab (CK-301; TG-1501) is a high-affinity, fully human PD-L1-blocking monoclonal antibody that binds PD-L1 and blocks its interaction with PD-1. Cosibelimab has a functional Fc domain and is capable of inducing ADCC and complement-dependent cytotoxicity (CDC)-mediated killing of PD-L1+ cell lines, including lymphoma cells. |
|
| A704 | Durvalumab Featured | Durvalumab (MEDI 4736) is an human anti-PD-L1 monoclonal antibody. Durvalumab (MEDI4736) completely blocks the binding of PD-L1 to both PD-1 and CD80, with IC50s of 0.1 and 0.04 nM, respectively. |
|
| A705 | Avelumab Featured | Avelumab is a fully human IgG1 anti-PD-L1 monoclonal antibody with potential antibody-dependent cell-mediated cytotoxicity. |
|
| A706 | Prezalumab Featured | Prezalumab (AMG 557) is a monoclonal antibody targeting ICOSL that has synergistic anti-inflammatory activity with CD28 antibody inhibitors. |
|
| A707 | Enoblituzumab Featured | Enoblituzumab (MGA271) is a humanized IgG1κ monoclonal antibody recognizing human B7-H3 protein, a member of the B7 family of immune regulators. |
|
| A708 | Omburtamab Featured | Omburtamab is an anti-CD276 (also known as B7-H3) monoclonal antibody, CD276 is a B7/CD28 immunoglobulin superfamily member expressed among solid human tumours. Omburtamab can bind tumor tissues and be used in various cancers research. |
|
| A709 | Trellis patent anti-B7-H3 Featured |
|
|
| A710 | Alsevalimab Featured | Alsevalimab is a human monoclonal antibody against B7-H4. |
|
| A711 | Millennium patent anti-B7-H4 Featured |
|
|
| A712 | Onvatilimab Featured | Onvatilimab (JNJ-61610588) is a human IgG1κ anti-VISTA (V-domain Ig Suppressor of T-cell Activation) monoclonal antibody. Onvatilimab has an anti-tumor activity. |
|
| A713 | Dartmouth patent anti-B7-H6 Featured |
|
